CLN5 Disease
Symptoms, Doctors, Treatments, Advances & More

Learn About CLN5 Disease

What is the definition of CLN5 Disease?

CLN5 disease is an inherited disorder that primarily affects the nervous system. The signs and symptoms of this condition can begin anytime between childhood and early adulthood, but they typically appear around age 5. Children with CLN5 disease often have normal development until they experience the first signs of the condition, which are usually problems with movement that might seem like clumsiness, and a loss of previously acquired motor skills (developmental regression). Other features of the condition include recurrent seizures that involve uncontrollable muscle jerks (myoclonic epilepsy), difficulty coordinating movements (ataxia), vision loss, speech problems, and a decline in intellectual function. The life expectancy of people with CLN5 disease varies; affected individuals usually survive into adolescence or mid-adulthood.

What are the causes of CLN5 Disease?

CLN5 disease is caused by mutations in the CLN5 gene, which provides instructions for making a protein whose function is not well understood. After the CLN5 protein is produced, it is transported to cell compartments called lysosomes, which digest and recycle different types of molecules. Research suggests that the CLN5 protein may play a role in the process by which lysosomes break down or recycle damaged or unneeded proteins within the cell.

How prevalent is CLN5 Disease?

The incidence of CLN5 disease is unknown; more than 85 cases have been described in the scientific literature. CLN5 disease was originally thought to affect only the Finnish population because they were the first individuals to be diagnosed with the condition. However, research has since shown that CLN5 disease affects populations worldwide. NCLs, including CLN5 disease, are still most common in Finland, where approximately 1 in 12,500 individuals are affected. Collectively, all forms of NCL affect an estimated 1 in 100,000 individuals worldwide.

Is CLN5 Disease an inherited disorder?

This condition is inherited in an autosomal recessive pattern, which means both copies of the gene in each cell have mutations. The parents of an individual with an autosomal recessive condition each carry one copy of the mutated gene, but they typically do not show signs and symptoms of the condition.

Who are the top CLN5 Disease Local Doctors?
Elite in CLN5 Disease
Elite in CLN5 Disease
Referral may be required
Hamburg, HH, DE 

Angela Schulz practices practicing medicine in Hamburg, Germany. Ms. Schulz is rated as an Elite expert by MediFind in the treatment of CLN5 Disease. She is also highly rated in 8 other conditions, according to our data. Her clinical expertise encompasses CLN2 Disease, CLN1 Disease, CLN4 Disease, CLN5 Disease, and Hepato-Pancreato-Biliary Surgery.

Elite in CLN5 Disease
Elite in CLN5 Disease
Referral may be required
Xinxiang, CN 

Zhongjian Zhang practices practicing medicine in Xinxiang, China. Zhang is rated as an Elite expert by MediFind in the treatment of CLN5 Disease. They are also highly rated in 6 other conditions, according to our data. Their clinical expertise encompasses CLN4 Disease, CLN5 Disease, CLN3 Disease, and CLN1 Disease.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in CLN5 Disease
Elite in CLN5 Disease
Referral may be required
London, ENG, GB 

Sara Mole practices practicing medicine in London, United Kingdom. Ms. Mole is rated as an Elite expert by MediFind in the treatment of CLN5 Disease. She is also highly rated in 6 other conditions, according to our data. Her clinical expertise encompasses CLN2 Disease, Batten Disease, CLN1 Disease, and CLN4 Disease.

What are the latest CLN5 Disease Clinical Trials?
Coordination of Rare Diseases at Sanford

Summary: The Coordination of Rare Diseases at Sanford (CoRDS) is an international patient registry that serves as a centralized resource for rare disease research. Individuals affected by rare diseases, undiagnosed conditions, and disorders of unknown prevalence may voluntarily contribute health information to support natural history studies, participant recruitment, and other research efforts. Through par...

Match to trials
Find the right clinical trials for you in under a minute
Get started
A First-in-Human, Open-Label, Dose-Escalation Study to Evaluate the Safety and Tolerability of Gene Therapy With TTX-381 for the Ocular Manifestations Associated With Neuronal Ceroid Lipofuscinosis Type 2 (CLN2) Disease

Summary: This is a registrational, first-in-human, open-label, dose escalation and expansion study evaluating the safety, tolerability and effectiveness of TTX-381, administered by injection under the retina, for the treatment of eye problems caused by CLN2 (Batten disease). The study includes dose escalation and expansion groups evaluating treatment in one or both eyes. Participants are followed for 5 yea...

Who are the sources who wrote this article ?

Published Date: February 03, 2021
Published By: National Institutes of Health